Last reviewed · How we verify

Kodiak Sciences Inc — Portfolio Competitive Intelligence Brief

Kodiak Sciences Inc pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tabirafusp tedromer Tabirafusp tedromer phase 3 IL-4 receptor alpha antagonist IL-4Rα Allergy
KSI-101 KSI-101 phase 3 Bispecific antibody VEGF and ANG-2 Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allakos Inc. · 1 shared drug class
  2. Allergan · 1 shared drug class
  3. Amgen · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Atom Therapeutics Co., Ltd · 1 shared drug class
  6. BioNTech SE · 1 shared drug class
  7. Coherus Oncology, Inc. · 1 shared drug class
  8. Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kodiak Sciences Inc:

Cite this brief

Drug Landscape (2026). Kodiak Sciences Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kodiak-sciences-inc. Accessed 2026-05-13.

Related